

Rec'd PCT/PTO 25 JUL 2005

10/519335 #4

AMENDMENT UNDER 37 CFR
§1.825(a) THROUGH (c)
Patent Application
Docket No. G-194US03PCT
Serial No. 10/519,335

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
first class mail in an envelope addressed to:

Commissioner for Patents, P.O. Box 1450
Alexandria, VA 22313 on July 22, 2005

Frank C Eisenschenk

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Laurent Cavarec, Ilya Chumakov, Benoit Destenaves, Catherine Gonthier,
Isabelle Elias
Serial No. : 10/519,335
Filed : December 22, 2004
Conf. No. : 9318
For : Novel KCNQ Polypeptides, Modulators Thereof, and Their Uses in the
Treatment of Mental Disorders

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313

AMENDMENT UNDER 37 CFR §1.825(a) THROUGH (c)

Sir:

In response to the Notification of Missing Requirements Under 35 U.S.C. 371 in the United States Designated/Elected Office (DO/EO/US) received in the above-identified patent application, please amend the subject application as follows, in order to comply with the requirements of 37 CFR §§1.821-1.825: